.png){kind=icon}
.png){kind=icon}
Return
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre Study-IL-AD (Italian Landscape Atopic Dermatitis)
.png){kind=icon}
PRE
AI
P
R
S
M
N
F
G
B
M
S
F
G
E
N
G
O
S
M
S
A
B
S
C
C
L
B
M
R
V
T
F
P
R
V
N
DOI：10.2340/actadv.v106.adv-2025-0193.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Abrocitinib, an oral selective Janus kinase 1 inhibitor, is approved for the treatment of moderate-tosevere atopic dermatitis (AD) in adults, but realworld evidence remains limited. We retrospectively collected data from 187 adult patients (mean age: 37.9 years; 60.4% male), with AD and up to oneyear exposure to abrocitinib either 100 or 200 mg, between 2023 and 2025 across 22 Italian dermatology centres. Nearly half of patients were bio-experienced and 80 % had difficult-to-treat areas. Beginning at week 8, with either 100 (59%) or 200 mg, 52 % achieved Investigator Global Assessment 0/1, significantly increasing to 88 % at week 52. Similarly, Eczema Area and Severity Index (EASI) and itch had significantly higher 1-year response: increasing from 27.8% and 34.7%, respectively, at week 8, 79.6 % achieved EASI-90 and 0/1. Minimal disease activity, a stringent composite endpoint, was met by 18 % at week 8 and by 66 % at week 52. Safety was good, with mild adverse events mostly including abdominal pain, upper respiratory infections and headache. The 100 mg dose had a significantly better safety profile, with efficacy similar to 200 mg. These data confirm the efficacy and safety of abrocitinib, with early, progressive clinical benefits sustained through 1 year.
Keywords:
Abrocitinib
Atopic Dermatitis
Efficacy
Itch
Minimal Disease Activity
Safety
Journal
A
IF:
3.7
Papers:
5.4K
Citations:
8.6K
Organization
Cited Papers